Candidiasis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Candidiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H2 2016', provides an overview of the Candidiasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Candidiasis Overview 8
Therapeutics Development 9
Pipeline Products for Candidiasis - Overview 9
Pipeline Products for Candidiasis - Comparative Analysis 10
Candidiasis - Therapeutics under Development by Companies 11
Candidiasis - Therapeutics under Investigation by Universities/Institutes 13
Candidiasis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Candidiasis - Products under Development by Companies 19
Candidiasis - Products under Investigation by Universities/Institutes 22
Candidiasis - Companies Involved in Therapeutics Development 23
Amplyx Pharmaceuticals, Inc. 23
Bakker Medical Srl 24
Biomar Microbial Technologies 25
Biosergen AS 26
Cellceutix Corporation 27
Cidara Therapeutics, Inc. 28
Daewoong Pharmaceutical Co., Ltd. 29
Dermala Inc 30
General Biologicals Corporation 31
Grupo Ferrer Internacional, S.A. 32
Hsiri Therapeutics, LLC 33
iCo Therapeutics Inc. 34
Matinas BioPharma Holdings, Inc. 35
Nanomerics Ltd 36
Novabiotics Limited 37
NovaDigm Therapeutics, Inc. 38
Onxeo SA 39
Scynexis, Inc. 40
Sealife PHARMA GMBH 41
TGV-Laboratories 42
Viamet Pharmaceuticals, Inc. 43
Wellstat Vaccines, LLC 44
Candidiasis - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
(clotrimazole + diclofenac sodium) - Drug Profile 55
(clotrimazole + diclofenac sodium) 1 - Drug Profile 56
61894700 - Drug Profile 57
AC-17 - Drug Profile 58
amphotericin B - Drug Profile 59
amphotericin B - Drug Profile 61
amphotericin B - Drug Profile 64
Antibody to Target Ece1 for Candidiasis - Drug Profile 65
APX-001 - Drug Profile 66
arasertaconazole - Drug Profile 67
BSG-005 - Drug Profile 68
candidiasis vaccine - Drug Profile 69
CD-101 - Drug Profile 70
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 73
CTIX-1502 - Drug Profile 74
Drug for Candidiasis - Drug Profile 75
DWP-06081 - Drug Profile 76
Forazoline A - Drug Profile 77
iCo-010 - Drug Profile 78
KSL-W - Drug Profile 79
MH-010 - Drug Profile 80
miconazole nitrate - Drug Profile 81
Monoclonal Antibodies for Candidiasis - Drug Profile 83
Monoclonal Antibody for Candidiasis - Drug Profile 84
Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 85
Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections - Drug Profile 86
mutanobactins - Drug Profile 87
Myc-102 - Drug Profile 88
NDV-3 - Drug Profile 89
NDV-3A - Drug Profile 91
NP-339 - Drug Profile 92
obliquumol - Drug Profile 93
Occidiofungin - Drug Profile 94
PAC-113 - Drug Profile 95
PMX-1408 - Drug Profile 97
PMX-1570 - Drug Profile 98
PMX-1576 - Drug Profile 99
PMX-1591 - Drug Profile 100
PMX-1625 - Drug Profile 101
PMX-519 - Drug Profile 102
PMX-70004 - Drug Profile 103
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 104
SCY-078 - Drug Profile 105
SLP-0901 - Drug Profile 108
SLP-0904 - Drug Profile 109
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 110
Small Molecule for Fungal Infections - Drug Profile 111
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 112
Small Molecules for Candidiasis - Drug Profile 113
Small Molecules for Candidiasis - Drug Profile 114
Small Molecules for Candidiasis - Drug Profile 115
Small Molecules for Fungal Infections - Drug Profile 116
Small Molecules for Fungal Infections - Drug Profile 117
Small Molecules for Systemic Candidiasis - Drug Profile 118
Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 119
Synthetic Peptides for Candidiasis - Drug Profile 120
Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 121
TOL-463 - Drug Profile 122
Vaccine for Fungal Infections - Drug Profile 123
Vaccine to Target Ece1 for Candidiasis - Drug Profile 124
VT-1161 - Drug Profile 125
Candidiasis - Dormant Projects 129
Candidiasis - Discontinued Products 133
Candidiasis - Product Development Milestones 134
Featured News & Press Releases 134
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 145
Disclaimer 146

List of Tables

Number of Products under Development for Candidiasis, H2 2016 14
Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Comparative Analysis by Unknown Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016 28
Candidiasis - Pipeline by Bakker Medical Srl, H2 2016 29
Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2016 30
Candidiasis - Pipeline by Biosergen AS, H2 2016 31
Candidiasis - Pipeline by Cellceutix Corporation, H2 2016 32
Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016 33
Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 34
Candidiasis - Pipeline by Dermala Inc, H2 2016 35
Candidiasis - Pipeline by General Biologicals Corporation, H2 2016 36
Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 37
Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2016 38
Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2016 39
Candidiasis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 40
Candidiasis - Pipeline by Nanomerics Ltd, H2 2016 41
Candidiasis - Pipeline by Novabiotics Limited, H2 2016 42
Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016 43
Candidiasis - Pipeline by Onxeo SA, H2 2016 44
Candidiasis - Pipeline by Scynexis, Inc., H2 2016 45
Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2016 46
Candidiasis - Pipeline by TGV-Laboratories, H2 2016 47
Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 48
Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2016 49
Assessment by Monotherapy Products, H2 2016 50
Assessment by Combination Products, H2 2016 51
Number of Products by Stage and Target, H2 2016 53
Number of Products by Stage and Mechanism of Action, H2 2016 55
Number of Products by Stage and Route of Administration, H2 2016 57
Number of Products by Stage and Molecule Type, H2 2016 59
Candidiasis - Dormant Projects, H2 2016 134
Candidiasis - Dormant Projects (Contd..1), H2 2016 135
Candidiasis - Dormant Projects (Contd..2), H2 2016 136
Candidiasis - Dormant Projects (Contd..3), H2 2016 137
Candidiasis - Discontinued Products, H2 2016 138